Fig. 1 · Structure

Documents & Downloads

Capivasertib (AZD5363)

Cat. No. A11759 CAS 1143532-39-1

AKT inhibitor

Capivasertib (AZD5363) is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.

In Stock

Publications for Capivasertib

6 publications citing this product

  1. Léa-Isabelle Renaud, .et al. , PLoS One, 2024, Jun 21;19(6):e0302042 PMID: 38905217
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. Hiroyuki Tsuchiya, .et al. , Curr Issues Mol Biol, 2023, Jan 29;45(2):1073-1085 PMID: 36826016
  4. Giri R. Gnawali, .et al. , Medicinal Chemistry Research, 2022, 31: 1154-1175 PMID: 36389181
  5. Jeremiah J Bearss, .et al. , EMBO Rep, 2021, Apr 7;22(4):e50835 PMID: 33586867
  6. Jin H. Song, .et al. , Mol Cancer Ther, 2018, Dec;17(12):2710-2721 PMID: 30190422

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In ER-positive breast cancer cells adapted to long-term estrogen deprivation, AZD5363 reduced downstream AKT-pathway phosphorylation while increasing phosphorylation of AKT itself. These cellular findings support evaluating downstream substrates alongside phospho-AKT when assessing pathway inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Akt1 IC50 3 nM
Akt2 IC50 7 nM
Akt3 IC50 7 nM
P70S6K IC50 6 nM
PKA IC50 7 nM
ROCK2 IC50 60 nM
ROCK1 IC50 470 nM
Autophagy  

8 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
769-P IC50 10.75 μM Antiproliferative activity against human 769-P cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
786-0 IC50 23.28 μM Antiproliferative activity against human 786-0 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
A549 IC50 23.67 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
AGS IC50 9.6 μM Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 34917257]
Bel-7402 IC50 49.6 μM Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
CHO IC50 > 100000 nM Inhibition of human ERG expressed in CHO cells by ionworks assay [PMID: 23394218]
HaCaT IC50 4.2 μM Antiproliferative activity against human HaCaT cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay [PMID: 34375113]
HCT-116 IC50 5.2 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 31298542]
HCT-116 IC50 5.2 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 27089211]
HepG2 IC50 6.7 μM Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
HT-29 IC50 36.92 μM Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
KHOS/NP IC50 40.42 μM Antiproliferative activity against human KHOS cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
LNCaP IC50 0.46 μM Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
LNCaP IC50 336.8 nM Inhibition of Akt in human PTEN-null LNCAP cells assessed as suppression in PRAS40 phosphorylation after 1 hr by ELISA analysis [PMID: 27089211]
MCF7 IC50 4.2 μM Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 34917257]
MDA-MB-231 IC50 60.52 μM Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB method [PMID: 34375113]
MDA-MB-468 GI50 3.8 μM Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth by measured after 5 days by IncuCyte zoom live cell analysis [PMID: 35119851]
MDA-MB-468 IC50 89 nM Inhibition of Akt in human MDA-MB-468 cells assessed as inhibition of GSK3beta phosphorylation after 2 hrs by laser scanning cytometry [PMID: 23394218]
NCI-H1975 IC50 2.7 μM Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 34917257]

19 records · Scroll to view more

Capivasertib (AZD5363) Research Summary

This section summarizes 3 in vitro studies of Capivasertib (AZD5363) from 2 published references. In vitro models include MCF-7/LTED, ZR75-1/LTED, MDA-361/LTED and HCC-1428/LTED cells.

Capivasertib (AZD5363) In Vitro Studies

AZD5363 at 0.4 or 2 µM suppressed growth in three of four LTED breast cancer cell lines over 5–10 days. HCC-1428/LTED remained unresponsive, showing that growth inhibition was model dependent. [1]

In HLF and HuH6 liver cancer cells, NEAT1v1 overexpression was associated with increased phospho-AKT and greater sensitivity to capivasertib in a 48-hour WST assay. The tested range was 25–400 µM, which limits conclusions about target specificity; the assay also does not distinguish growth arrest from cell death. [2]

AKT-pathway response in ER-positive LTED breast cancer cells

Cell-based study · MCF-7/LTED, ZR75-1/LTED, MDA-361/LTED and HCC-1428/LTED cells [1]

AZD5363 reduced downstream substrate phosphorylation while increasing AKT phosphorylation. Response varied among cell lines; phospho-AKT alone should not be treated as a readout of preserved catalytic activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylation of PRAS40, GSK-3 and S6, with AKT phosphorylation at T308 and S473Qualitative immunoblot response Reduced downstream phosphorylation with increased phospho-AKT; effects vary by cell line[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 2, 5, 10 and 15 µM (Figure 1A labels)
Exposure duration
24 hours
Method
Immunoblotting after treatment in 10% dextran/charcoal-treated FBS
Vehicle
No-drug control; solvent identity/concentration not established from the read passages
Reported limits
No direct binding or isolated-enzyme assay in this experiment; replicate number for Figure 1A not specified in its caption.
Methods and source locations

Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: AZD5363

Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.

Figure 1A and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell lines; Immunoblot analysis and RTK arrays

Phosphorylation of PRAS40, GSK-3 and S6, with AKT phosphorylation at T308 and S473: Figure 1A includes actin, total S6 and phospho-AKT bands; no numerical band quantification adopted. — Figure 1A and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell lines; Immunoblot analysis and RTK arrays

Model-dependent growth inhibition in LTED breast cancer cells

Cell-based study · MCF-7/LTED, ZR75-1/LTED, MDA-361/LTED and HCC-1428/LTED cells [1]

Growth was suppressed in three of four LTED lines at concentrations ≤2 µM. HCC-1428/LTED was unresponsive under these conditions, despite the biochemical pathway effects seen in the companion signaling experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Adherent cell number relative to control in four LTED linesPercent of control; qualitative model comparison Growth suppressed in MCF-7/LTED, ZR75-1/LTED and MDA-361/LTED; HCC-1428/LTED unresponsive. Bars: mean ± SEM, n = 3; caption reports *P < 0.0001 versus control, one-way ANOVA.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.4 or 2 µM AZD5363 versus no-drug control
Exposure duration
5–10 days; media and drugs replenished every three days
Method
Triplicate cultures in 10% DCC-FBS; adherent cells counted with a Coulter Counter
Vehicle
No-drug control; solvent identity/concentration not established from read passages
Reported limits
Exact day for each line is not specified in Figure 1B; n=3 is preserved as reported rather than called independent biological replicates.
Methods and source locations

Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: AZD5363

Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.

Figure 1B and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell proliferation; Statistics

Adherent cell number relative to control in four LTED lines: Cell counting. Exact bar heights and IC50 values were not inferred from the image. — Figure 1B and caption; Results: Inhibition of AKT suppresses hormone-independent breast cancer cell growth; Methods: Cell proliferation; Statistics

NEAT1v1-associated capivasertib sensitivity in liver cancer cells

Cell-based study · HLF and HuH6 control cells versus stable NEAT1v1-overexpressing cells [2]

NEAT1v1-overexpressing cells showed increased phospho-AKT and greater loss of WST signal with capivasertib than control cells at several concentrations. This is a model-specific association, not proof of exclusive AKT-mediated cytotoxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
WST-derived viability in NEAT1v1-overexpressing versus control HLF and HuH6 cellsRelative viability (% DMSO control) Greater sensitivity with NEAT1v1 overexpression at several tested concentrations; mean ± SD, n = 4; *p < 0.05 versus CTRL, Student’s t-test. No exact viability percentages or IC50 values extracted.[2]
Baseline phospho-AKT in NEAT1v1-overexpressing versus control cellsQualitative immunoblot Higher phospho-AKT in overexpressing cells, particularly HuH6[2]

Literature-Reported Treatment Conditions

Treatment concentration
25, 50, 100, 200 and 400 µM capivasertib; DMSO control (0 µM)
Exposure duration
48 hours of drug treatment
Method
Cell Counting Kit-8 WST viability assay; accompanying phospho-AKT immunoblot comparison
Vehicle
DMSO; each cell background normalized to its own DMSO control (100%)
Reported limits
DMSO percentage and product catalog/lot identity not established. Supplemental Table S1 was not retrieved. WST signal does not distinguish cytostasis from cell death.
Methods and source locations

Compound reported in the paper: Capivasertib (AZD5363); Compound label in the paper: capivasertib

Compound-level research findings only. No salt conversion, product-lot validation or clinical efficacy inference.

Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6

WST-derived viability in NEAT1v1-overexpressing versus control HLF and HuH6 cells: Figure 3D concentration labels read directly from viewed image; n and test from caption; SD semantics from Section 2.6. — Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6

Baseline phospho-AKT in NEAT1v1-overexpressing versus control cells: Figure 3C includes total AKT and GAPDH; no densitometry adopted. — Figure 3C-D and caption; Results Section 3.3; Methods Sections 2.1, 2.3, 2.5 and 2.6

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1143532-39-1
Applications AKT inhibitor
Formula C21H25ClN6O2
Molecular Weight 428.9
Synonyms AZD 5363
SMILES
C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (184.18 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Capivasertib (AZD5363) Research References

  1. [1] Fox EM, Kuba MG, Miller TW, et al. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast cancer research : BCR (2013). PMID: 23844554 DOI: 10.1186/bcr3449 Source material
  2. [2] Tsuchiya H, Shinonaga R, Sakaguchi H, et al. NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. Current issues in molecular biology (2023). PMID: 36826016 DOI: 10.3390/cimb45020071 Source material

Publications

6 publications citing this product

  1. Léa-Isabelle Renaud, .et al. , PLoS One, 2024, Jun 21;19(6):e0302042 PMID: 38905217
  2. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  3. Hiroyuki Tsuchiya, .et al. , Curr Issues Mol Biol, 2023, Jan 29;45(2):1073-1085 PMID: 36826016
  4. Giri R. Gnawali, .et al. , Medicinal Chemistry Research, 2022, 31: 1154-1175 PMID: 36389181
  5. Jeremiah J Bearss, .et al. , EMBO Rep, 2021, Apr 7;22(4):e50835 PMID: 33586867
  6. Jin H. Song, .et al. , Mol Cancer Ther, 2018, Dec;17(12):2710-2721 PMID: 30190422

Added to your cart

View Cart Checkout
Loading...